Streetbeat News

Equity Actions

COP

Analysts have mixed views on ConocoPhillips (NYSE:COP), with recent evaluations showing a shift towards a more cautious stance. The average 12-month price target has been reduced by 4.27% to $134.5. Despite this, ConocoPhillips maintains strong financial indicators, including a high net margin and ROE, but faces challenges in revenue growth. The company's market position remains robust, with significant scale and a prudent approach to debt management.

Portfolio Pulse from Benzinga Insights

February 09, 2024 | 7:01 pm

FAF

First American Financial (NYSE:FAF) received mixed analyst ratings, with a recent shift towards a more bullish outlook. The average 12-month price target is $67.00, slightly down from the previous target. The company faces challenges in revenue growth, net margin, ROE, ROA, and debt management, indicating potential difficulties ahead.

Portfolio Pulse from Benzinga Insights

February 09, 2024 | 7:00 pm

TBBB

BBB Foods has officially opened its IPO shares for trade, with the initial offering priced at $17.50 per share, covering a total of 33.7 million shares.

Portfolio Pulse from Benzinga Newsdesk

February 09, 2024 | 5:59 pm

AMZN

ETSY

MGM

MMYT

NKE

OLLI

PLAY

PLCE

TSLA

Today's session highlighted significant whale activity in the consumer discretionary sector, with notable options trading on stocks like TSLA, AMZN, MMYT, NKE, MGM, ETSY, PLAY, OLLI, PLCE, and RH. The trades varied in sentiment from bullish to bearish, indicating diverse market expectations. This activity could signal upcoming volatility or shifts in these stocks, making them ones to watch for traders.

Portfolio Pulse from Benzinga Insights

February 09, 2024 | 5:35 pm

MAA

Mid-America Apartment (NYSE:MAA) received mixed analyst ratings over the past three months, with a total of 7 ratings. The sentiment has shifted towards a more neutral stance in the last 30 days. The 12-month price targets show an average of $135.29, indicating a 2.11% increase from the previous target. Analyst actions include maintaining, raising, and lowering ratings and price targets, reflecting their response to market conditions and company performance. MAA, a real estate investment trust, has shown positive revenue growth, impressive net margin, and strong ROE and ROA, despite lagging behind industry peers in revenue growth.

Portfolio Pulse from Benzinga Insights

February 09, 2024 | 5:00 pm

CXW

Wedbush has reaffirmed its Outperform rating on CoreCivic (NYSE:CXW) and increased its price target from $17.00 to $18.00. CoreCivic's shares have risen 3.6% in the last 24 hours to $15.54. The new price target suggests a potential upside of 15.83%. CoreCivic, a company that operates private prisons and detention centers, has seen the majority of its revenue come from its Safety segment.

Portfolio Pulse from Benzinga Insights

February 09, 2024 | 5:00 pm

VLCN

Volcon's (NYSE:VLCN) short interest has decreased by 38.83% since the last report, with 796 thousand shares sold short, representing 6.98% of its float. This decrease in short interest could indicate a more bullish sentiment towards VLCN among traders. The current short interest is significantly higher than the peer group average of 2.76%, suggesting that VLCN has more bearish sentiment compared to its peers.

Portfolio Pulse from Benzinga Insights

February 09, 2024 | 4:30 pm

HLXB

Helix Acquisition Corp II has officially opened its IPO shares for trade, marking a significant milestone for the company.

Portfolio Pulse from Benzinga Newsdesk

February 09, 2024 | 4:09 pm

CVM

CEL-SCI Corporation (NASDAQ:CVM) shares dropped 13.9% to $2.46 after announcing a stock offering of 3.875 million shares at $2.00 each, aiming to raise $7.75 million for Multikine development, general corporate purposes, and working capital. The offering is managed by ThinkEquity and is expected to close on February 13, 2024. The funds will support the commercial-scale production of Multikine for head & neck cancer.

Portfolio Pulse from Henry Khederian

February 09, 2024 | 4:06 pm

BTAI

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) shares fell after announcing a public offering of $60 million in common stock or pre-funded warrants. The offering includes a 30-day option for underwriters to purchase up to $9 million additional shares. Proceeds will fund clinical trials, commercialization, and general corporate purposes. This follows the completion of patient enrollment in a Phase 2 trial of BXCL701 with KEYTRUDA for metastatic pancreatic cancer. BTAI shares dropped 33% to $2.5115.

Portfolio Pulse from Nabaparna Bhattacharya

February 09, 2024 | 4:05 pm